Corona Remedies Limited · NSE:CORONA
Corona Remedies — Q3 FY26 Earnings Presentation
31 slides from Corona Remedies's earnings presentation, February 2026
Slide 1: CORONA Remedies Limited Investor Presentation: February 2026
CORONA Remedies Limited Investor Presentation: February 2026
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by CORONA Remedies Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 3: Contents
Contents Operational & Financial Performance Financial & Operational Performance for Q3 and 9M FY26 About us Overview of CORONA Focused Brand Building Approach Strong brand recall across Therapeutic Areas CORONA : Outpacing IPM Growth CORONA vs. IPM Road Ahead Key Growth Strategies Annexures Histori
Slide 4: Key Highlights for Q3 & 9MFY26
Key Highlights for Q3 & 9MFY26 Financial Highlights Return Ratios Key Highlights Q3FY26 (Y-o-Y) 9MFY26 (Y-o-Y) 9MFY26 ✓ Reported healthy revenue growth of 15% during Q3 and 16.3% in 9M FY26 on a Y-o-Y basis, supported by INR 342 Cr INR 1,050 Cr 48.0% brand strength and distribution REVENUE network.
Slide 5: Financial Highlights – Q3 & 9MFY26
Financial Highlights – Q3 & 9MFY26 Revenue (INR Crores) EBITDA (INR Crores) Adjusted PAT* (INR Crores) 16.3% 24.6% 30.7% 1,050.1 231.4 154.1 902.7 185.8 117.9 15.0% 19.8% 23.7% 342.4 83.2 55.6 297.7 69.4 45.0 Q3FY25 Q3FY26 9MFY25 9MFY26 Q3FY25 Q3FY26 9MFY25 9MFY26 Q3FY25 Q3FY26 9MFY25 9MFY26 EBITDA
Slide 6: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (INR Crores) Q3FY26 Q3FY25 Y-o-Y 9MFY26 9MFY25 Y-o-Y Revenue from Operations 342.4 297.7 15.0% 1,050.1 902.7 16.3% Cost of Goods Sold 60.3 55.2 194.7 179.7 Gross Profit 282.2 242.5 855.4 723.1 Gross Profit Margin 82.4% 81.5% 81.5% 80.1% Employee C
Slide 7: Contents
Contents Operational & Financial Performance Financial & Operational Performance for Q3 and 9M FY26 About us Overview of CORONA Focused Brand Building Approach Strong brand recall across Therapeutic Areas CORONA : Outpacing IPM Growth CORONA vs. IPM Road Ahead Key Growth Strategies Annexures Histori
Slide 8: CORONA Remedies at a Glance
CORONA Remedies at a Glance 16.8% 71.6% Jumped 8 ranks 96.3% Revenue CAGR 1 in 3 years Revenue from India Chronic portfolio Business contribution Over MAT Jun-22 to 1.82x growth MAT Jun-25 for 9MFY26 for 9MFY26 compared to IPM 1 EU-GMP, EAEU- #5 in Women’s Healthcare GMP & WH0-GMP 71 Brands with #5
Slide 9: Journey over the years
Journey over the years ❖ In -licensing arrangement with Ferring ❖ Launch of 1st cardiological Pharmaceuticals Private Limited to ❖ Acquisition of 7 brands from ❖ Founded in 2004 and division: Wellness market certain products under women’s Bayer Zydus Pharma Ltd launch of first division, ❖ Purchased
Slide 10: CORONA's 3C Philosophy
CORONA’s 3C Philosophy Culture • Ruthless Execution • Internal Promotion • Adaptability • Humbleness Courage CORONA’s • Accepting Mistakes 3C and improving • Robust Inorganic Philosophy Opportunities Commitment • Global Quality Products • Value Creation for Stakeholders • Long Term Sustainable Growt
Slide 11: Quality Focused State of the Art Manufacturing Facilities
Quality Focused State of the Art Manufacturing Facilities Himachal Pradesh Total Installed Capacity Gujarat Installed capacity of ~403 Mn tablets/capsules & 10 Mn liquid Installed capacity of ~1.25 bottles Bn* tablets/capsules & 20 Formulations* WHO-GMP & Uganda NDA Mn sachets certifications Certifi
Slide 12: Professional Senior Management Leading the Way
Professional Senior Management Leading the Way Niravkumar Kritikumar Mehta Ankur Kritikumar Mehta Viral Bhupendrabhai Sitwala Managing Director & CEO Joint Managing Director Whole-Time Director Over 2 decades of experience in the Over 2 decades of experience in the Over 2 decades of experience in th
Slide 13: Experienced Board of Directors
Experienced Board of Directors Niravkumar Kritikumar Mehta Ankur Kritikumar Mehta Viral Bhupendrabhai Sitwala Dr. Kiritkumar Laxmidas Mehta Managing Director & CEO Joint Managing Director Whole-Time Director Chairman and Non-Executive Director Ameetkumar Hiranyakumar Desai Monica Kanuga Shirish Gund
Slide 14: ESG @ CORONA Remedies
ESG @ CORONA Remedies • Existing solar power plant of 1.3 MW at Bhayla Plant and investment for 4.25 MW in Solar Park E Spread across 11.9 Acres which will save significant electricity cost • Protection of Environment by Tree Plantation, Distribution of Plant Saplings, initiatives like wearing un-ir
Slide 15: Contents
Contents Operational & Financial Performance Financial & Operational Performance for Q3 and 9M FY26 About us Overview of CORONA Focused Brand Building Approach Strong brand recall across Therapeutic Areas CORONA : Outpacing IPM Growth CORONA vs. IPM Road Ahead Key Growth Strategies Annexures Histori
Slide 16: Engine Brands approach with Successful Scaling Up of Brands
“Engine” Brands approach with Successful Scaling Up of Brands 27 Engine Brands Established track record of building and scaling brands Brands with Sales ~72% 29 >INR 10 Crs 38 Contribution to Domestic Sales over MAT Jun-22 to MAT Jun-25 1 6 ~21% CAGR over 0 1 MAT Jun-22 to MAT Jun-25 7 No. of Brands
Slide 17: Acquisition & Strategic Collaborations for India Business
Acquisition & Strategic Collabourations for India Business Strategic collabourations for India Significantly scaled-up acquired brands Business Sr. No Acquired From Brands Ferring Pharmaceuticals, Switzerland Thyrocab 1 ABBOTT India Limited In-Licensing Arrangement for certain products in Obimet Wom
Slide 18: Strategic Portfolio Diversification & Brand Development
Strategic Portfolio Diversification & Brand Development 12.4% 13.5% West Geography South Expanding and diversifying Wise 21.5% 48.0% 20.2% 46.3% FY23 FY25 North geographical presence to strengthen East and deepen pan-India penetration 18.0% 20.0% Therapy Wise 27.5% Women’s Healthcare 29.3% 42.3% 34.
Slide 19: Contents
Contents Operational & Financial Performance Financial & Operational Performance for Q3 and 9M FY26 About us Overview of CORONA Focused Brand Building Approach Strong brand recall across Therapeutic Areas CORONA : Outpacing IPM Growth CORONA vs. IPM Road Ahead Key Growth Strategies Annexures Histori
Slide 20: Indian Pharmaceutical Market: High-Growth Landscape
Indian Pharmaceutical Market : High-Growth Landscape IPM is poised to grow at CAGR of 8-9% till FY30 Growth drivers for domestic formulations industry INR Trillion 3.1 2.3 Improving life expectancy and changing 2.1 1.8 1.9 demographic profile 1.5 1.5 01 Rising prevalence of chronic diseases FY20 FY2
Slide 21: CORONA Remedies: Demonstrated 1.82x Growth compared to IPM
CORONA Remedies: Demonstrated 1.82x Growth compared to IPM CORONA has grown at 1.82x compared to IPM growth[1] Growth driven by volume, price and new product launches 16.8% 6.6% IPM CORONA 5.7% 5.3% 4.6% 9.2% 2.2% 1.7% Average yearly Average yearly Average yearly CORONA Remedies IPM Average volume g
Slide 22: Cementing position in Chronic segment with focus on Key Therapies
Cementing position in Chronic segment with focus on Key Therapies Women’s Healthcare Cardio-Diabeto Pain Management Urology CORONA Remedies vis-à-vis 2.27x 2.25x 1.56x 3.56x IPM CAGR[2] 20.7% 22.0% 19.2% 59.6% 12.3% 9.1% 9.7% 16.8% IPM CORONA IPM CORONA IPM CORONA IPM CORONA Women’s Healthcare Cardi
Slide 23: Contents
Contents Operational & Financial Performance Financial & Operational Performance for Q3 and 9M FY26 About us Overview of CORONA Focused Brand Building Approach Strong brand recall across Therapeutic Areas CORONA : Outpacing IPM Growth CORONA vs. IPM Road Ahead Key Growth Strategies Annexures Histori
Slide 24: Future Growth Strategies
CORONA Remedies Limited Future Growth Strategies • Improve MR productivity, expanding prescriber base and increasing the number of products Increase market share 1 within the domestic IPM prescribed per prescriber • Intensify engagement with super-specialist prescribers in metro, semi-metro, and urb
Slide 25: Contents
Contents Operational & Financial Performance Financial & Operational Performance for Q3 and 9M FY26 About us Overview of CORONA Focused Brand Building Approach Strong brand recall across Therapeutic Areas CORONA : Outpacing IPM Growth CORONA vs. IPM Road Ahead Key Growth Strategies Annexures Histori
Slide 26: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Profit and Loss (INR Crores) FY25 FY24 FY23 Revenue from Operations 1,196.4 1,014.5 884.1 Cost of Goods Sold 236.5 226.8 211.0 Gross Profit 959.9 787.6 673.1 Gross Margin (%) 80.2% 77.6% 76.1% Employee Cost 346.1 295.4 254.8 Other Expenses 373.8 337.5
Slide 27: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Assets (INR Crores) Mar-25 Mar-24 Mar-23 Equity & Liabilities (INR Crores) Mar-25 Mar-24 Mar-23 Non - Current Assets 591.0 540.7 303.5 Total Equity 606.3 480.4 408.5 Property, plant and equipment 198.7 191.0 184.1 Share Capital 61.2 61.2 61.2 Capital work-in-pro
Slide 28: Historical Consolidated Abridged Cash Flow Statement
Historical Consolidated Abridged Cash Flow Statement Particulars (INR Crores) FY25 FY24 FY23 Net Profit Before Tax 198.5 118.5 110.9 Adjustments for: Non -Cash Items / Other Investment or Financial Items 52.3 46.9 22.6 Operating profit before working capital changes 250.8 165.3 133.4 Changes in work
Slide 29: Historical Financial Statement
Historical Financial Statement Revenue (INR Crores) EBITDA (INR Crores) PAT (INR Crores) 1,196.4 240.0 231.4 149.4 154.1 1,014.5 1,050.1 884.1 154.7 84.9 90.5 128.0 FY23 FY24 FY25 9MFY26 FY23 FY24 FY25 9MFY26 FY23 FY24 FY25 9MFY26* EBITDA Margin (%) PAT Margin (%) 22.0% 14.7% 20.1% 12.5% 14.5% 15.3%
Slide 30: Historical Financial Ratios
Historical Financial Ratios ROCE (%) ROE (%) 48.0% 31.1% 41.3% 27.5% 23.3% 31.2% 20.4% 28.4% FY23 FY24 FY25 9MFY26* FY23 FY24 FY25 9MFY26* OCF/EBITDA (%) Net working Capital Days 101.3% 31 86.3% 80.2% 79.4% 23 24 18 FY23 FY24 FY25 9MFY26 FY23 FY24 FY25 9MFY26 *ROE and ROCE for 9MFY26 is annualised &
Slide 31: Thank You
THANK YOU For further information, please contact: CORONA Remedies Limited Strategic Growth Advisors Private Limited (SGA) CIN: L24231GJ2004PLC044656 CIN: U74140MH2010PTC204285 Ms. Chetna Dharajiya – Company Secretary & Compliance Officer Mr. Sagar Shroff / Mr. Tanay Shah sagar.shroff@sgapl.net / ta